IL318381A - Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention - Google Patents

Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention

Info

Publication number
IL318381A
IL318381A IL318381A IL31838125A IL318381A IL 318381 A IL318381 A IL 318381A IL 318381 A IL318381 A IL 318381A IL 31838125 A IL31838125 A IL 31838125A IL 318381 A IL318381 A IL 318381A
Authority
IL
Israel
Prior art keywords
kars
tricyclic
methods
inhibitor dosing
akr1c3
Prior art date
Application number
IL318381A
Other languages
Hebrew (he)
Inventor
Christy Fryer
Lisa Kattenhorn
Margaret Elise Mclaughlin
Jeffrey Stonehouse
Heiko Maacke
Laurent L'epicier-Sansregret
Original Assignee
Novartis Ag
Christy Fryer
Lisa Kattenhorn
Margaret Elise Mclaughlin
Jeffrey Stonehouse
Heiko Maacke
Lepicier Sansregret Laurent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Christy Fryer, Lisa Kattenhorn, Margaret Elise Mclaughlin, Jeffrey Stonehouse, Heiko Maacke, Lepicier Sansregret Laurent filed Critical Novartis Ag
Publication of IL318381A publication Critical patent/IL318381A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL318381A 2022-07-26 2023-07-18 Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention IL318381A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369399P 2022-07-26 2022-07-26
PCT/IB2023/057314 WO2024023641A1 (en) 2022-07-26 2023-07-18 Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention

Publications (1)

Publication Number Publication Date
IL318381A true IL318381A (en) 2025-03-01

Family

ID=87555041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318381A IL318381A (en) 2022-07-26 2023-07-18 Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention

Country Status (11)

Country Link
US (1) US20260007654A1 (en)
EP (1) EP4561702A1 (en)
JP (1) JP2025526359A (en)
KR (1) KR20250040691A (en)
CN (1) CN119486737A (en)
AU (1) AU2023314349A1 (en)
CA (1) CA3258544A1 (en)
IL (1) IL318381A (en)
MX (1) MX2025000969A (en)
TW (1) TW202404589A (en)
WO (1) WO2024023641A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2016145092A1 (en) 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
UY38806A (en) 2019-08-01 2021-02-26 Novartis Ag AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES
IL300833A (en) * 2020-09-02 2023-04-01 Ascentawits Pharmaceuticals Ltd Akr1c3 detection method, and diagnostic kit for detecting akr1c3 and use thereof

Also Published As

Publication number Publication date
CN119486737A (en) 2025-02-18
TW202404589A (en) 2024-02-01
AU2023314349A1 (en) 2024-11-21
EP4561702A1 (en) 2025-06-04
US20260007654A1 (en) 2026-01-08
MX2025000969A (en) 2025-03-07
JP2025526359A (en) 2025-08-13
CA3258544A1 (en) 2024-02-01
WO2024023641A1 (en) 2024-02-01
KR20250040691A (en) 2025-03-24

Similar Documents

Publication Publication Date Title
IL287792A (en) Tricyclic akr1c3 dependent kars inhibitors
IL291933A (en) Compositions of oligonucleotides and methods of using them
ZA202205938B (en) Small molecule inhibitors of kras g12c mutant
SG11202104927QA (en) Improved synthesis of key intermediate of kras g12c inhibitor compound
EP3856742C0 (en) TRICYCLIC JANUS KINASE-1 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF
DK3442973T3 (en) PREVIOUSLY UNKNOWN COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
IL308476A (en) Inhibitors of the menin-mll interaction
IT201600104717A1 (en) TENSIOACTIVE COMPOSITIONS FOR THE TREATMENT OF UNDERGROUND FORMATIONS AND OIL PRODUCTS
IL288387A (en) Small molecule inhibitors of nf-kb inducing kinase
EP3748653C0 (en) DC BASIN INSULATOR
MA50250A (en) TETRAHYDROIMIDAZO QUINOLEIN COMPOSITIONS USED AS CBP / P300 INHIBITORS
SG11202104192TA (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
DK3816247T3 (en) HARDENING MIXTURE
EP4003986A4 (en) INHIBITOR COMPOUNDS
EP3402521A4 (en) INHIBITION OF ALLERGIC REACTION USING IL-33 INHIBITOR
SG11202008925VA (en) Inhibitors of micro-rna 22
ZA202110347B (en) Bicyclic compound as rip-1 kinase inhibitor and application thereof
IL290324A (en) Compositions of trofinetide
GB201905328D0 (en) Inhibitor compounds
IL284343A (en) Equipment for aiding the traceability of agri-food products
HK40120424A (en) Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention
CY1124258T1 (en) COMPOUNDS USEFUL FOR INHIBITING ROR-γ-t
DK4013756T3 (en) MLL1 inhibitors and anticancer agents
DK3595442T3 (en) MICROCAPE-LEADED NITRIFICATION INHIBITOR COMPOSITIONS
CA3258544A1 (en) Methods of tricyclic akr1c3 dependent kars inhibitor dosing